Latest chemotherapy Stories
Completion of Enrollment Expected in 2015; Progression-Free Survival Data Expected in mid-2016 LOS ANGELES, Sept.
BOGOTA, Colombia, Sept.
Children who are exposed to chemotherapy or radiotherapy while in the womb suffer no negative impacts on mental or cardiac development, international studies presented at the ESMO 2014 Congress in Madrid have shown.
- LUX-Lung 8 trial met its primary endpoint of improving progression-free survival in patients treated with afatinib versus erlotinib after failure of first-line, platinum-based chemotherapy, reducing
BONN, Germany, September 29, 2014 /PRNewswire/ -- Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal
Final data after 49-month follow-up analysis in chemotherapy-naïve men with metastatic castration-resistant prostate cancer presented at European Society for Medical Oncology (ESMO) 2014 Congress
LUGANO, Switzerland, September 22, 2014 /PRNewswire/ -- Helsinn Group, a company focused on building quality cancer care, today announces that it is supporting an independent
A wild berry native to North America may strengthen the effectiveness of a chemotherapy drug commonly used to treat pancreatic cancer, reveals research published online in the Journal of Clinical Pathology.
Intravenous therapy, commonly known as IV therapy, is known as the administration of a liquid substance directly into a vein. It is also known as drip therapy, because most often the liquid is suspended above the IV site by an infusion pump, and runs through a drip chamber, which prevents air from entering the line. IVs are the preferred method of drug administration in hospital settings because they are the fastest known route of getting medication to the body. Intravenous therapy can also...
Antiviral Chemistry & Chemotherapy is a peer-reviewed academic journal published bi-monthly by International Medical Press in London since 1997. When founded in January 1990, it was published by Blackwell Science. The current editor-in-chief is Hugh J. Field of University of Cambridge, UK. The journal publishes primary papers and reviews on all aspects of the preclinical development of antiviral agents, including their chemical synthesis, biochemistry, pharmacology, mode of action and...